Benyettou, FarahFahs, H.Elkharrag, R.Bilbeisi, Rana A.Asmaa, BouakazRezgui, RachidMotte, LaurenceMagzoub, MazinBrandel, J.Olsen, John-CarlPiano, F.Gunsalus, K. C.Platas-Iglesias, CarlosTrabolsi, Ali2019-11-052019-11-052017-05-031 F. Benyettou, H. Fahs, R. Elkharrag, R. A. Bilbeisi, B. Asma, R. Rezgui, L. Motte, M. Magzoub, J. Brandel, J. C. Olsen, F. Piano, K. C. Gunsalus, C. Platas-Iglesias and A. Trabolsi, RSC Adv., 2017, 7, 23827–23834.2046-2069http://hdl.handle.net/2183/24243[Abstract] Cucurbit[7]uril-modified iron-oxide nanoparticles (CB[7]NPs) were loaded with doxorubicin hydrochloride (Dox) and tested as a drug delivery system. Dox was found to interact with the carbonyl-rich rims of the CB[7] macrocycles adsorbed on the surface of the nanoparticles. The Dox-loaded nanoparticles (Dox@CB[7]NPs) were stable at room temperature and physiological pH and released their Dox cargo under acidic conditions, in the presence of glutathione, or with heating. Dox@CB[7]NPs reduced the viability of HeLa and three other cancer-derived cell lines in vitro at lower IC50 than free Dox. They were also nontoxic to C. elegans. The sensitivity of HeLa cells to Dox@CB[7]NPs was enhanced when the temperature was elevated by application of an alternating magnetic field. Thus, Dox@CB[7]NPs show promise as agents for the intracellular delivery of Dox to cancer cells, for the selective and controlled release of the drug, and, more generally, as a possible means of combining chemotherapeutic and hyperthermic treatment modalities.engAtribución 3.0 Españahttp://creativecommons.org/licenses/by/4.0/es/Iron oxideDoxorubicinCurcubit[7]urilCancerHyperthermiajournal articleopen access